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Significant progress in the diagnosis and treatment of 
rare solid tumours such as soft tissue and bone sarcomas, 
which occurred in recent years, is the result of the con-
centration of patients with these cancers in specialised 
reference centres, international cooperation, and the 
achievements of molecular diagnostics. The key in the 
management of primary cancer as well as in the case of 
recurrence of the disease is planned multidisciplinary 
treatment — a combination of surgery (basic method) 
with radiotherapy (RTH) and/or chemotherapy (CTH) 
and physiotherapy [1–4]. Thanks to this, the chances of 
limiting the scope of resection and obtaining long-term 
survival or cure are significantly increased.
Modern, individualised combined therapy, including 
reconstructive procedures, saves the limb in the majority 
of patients with sarcomas of the aforementioned loca-
tion (in reference centres amputations are currently 
performed in less than 10% of patients). There is 
a steady but slow increase in the percentage of patients 
with sarcomas with long-term survival (the current five-
-year survival rate for sarcomas with a limb localisation 
is 55–78%). The prognosis at the metastatic stage is still 
poor (median survival: about 12–18 months). Favourable 
local results are achieved only by patients with sarcoma 
after scheduled (previous biopsy and comprehensive 
imaging multidisciplinary evaluation) complete exci-
sion of the primary lesion within the microscopically 
tumour-free margins (resection R0).
Following correct diagnosis, the majority of patients 
after complete resection require supplemental RTH (soft 
tissue sarcomas) or perioperative chemotherapy (bone sar-
comas) and many weeks’ rehabilitation, and control for at 
least five years in the centre that carried out the treatment. 
The introduction of drugs targeting molecular or genetic 
alterations in cells that participate in aetiopathogenesis 
(e.g. denosumab in giant cell tumour of bone, kinase 
inhibitors in gastrointestinal stromal tumours, or imatinib 
in dermatofibrosarcoma protuberans [DFSP]) has also 
contributed to the improved prognosis of patients [3–5].
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